Advertisement

Neurotherapeutics

, Volume 12, Issue 1, pp 185–199 | Cite as

Neuroprotective Properties of Cannabigerol in Huntington’s Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice

  • Sara Valdeolivas
  • Carmen Navarrete
  • Irene Cantarero
  • María L. Bellido
  • Eduardo Muñoz
  • Onintza Sagredo
Original Article
First Online:

Abstract

Different plant-derived and synthetic cannabinoids have shown to be neuroprotective in experimental models of Huntington’s disease (HD) through cannabinoid receptor-dependent and/or independent mechanisms. Herein, we studied the effects of cannabigerol (CBG), a nonpsychotropic phytocannabinoid, in 2 different in vivo models of HD. CBG was extremely active as neuroprotectant in mice intoxicated with 3-nitropropionate (3NP), improving motor deficits and preserving striatal neurons against 3NP toxicity. In addition, CBG attenuated the reactive microgliosis and the upregulation of proinflammatory markers induced by 3NP, and improved the levels of antioxidant defenses that were also significantly reduced by 3NP. We also investigated the neuroprotective properties of CBG in R6/2 mice. Treatment with this phytocannabinoid produced a much lower, but significant, recovery in the deteriorated rotarod performance typical of R6/2 mice. Using HD array analysis, we were able to identify a series of genes linked to this disease (e.g., symplekin, Sin3a, Rcor1, histone deacetylase 2, huntingtin-associated protein 1, δ subunit of the gamma-aminobutyric acid-A receptor (GABA-A), and hippocalcin), whose expression was altered in R6/2 mice but partially normalized by CBG treatment. We also observed a modest improvement in the gene expression for brain-derived neurotrophic factor (BDNF), insulin-like growth factor-1 (IGF-1), and peroxisome proliferator-activated receptor-γ (PPARγ), which is altered in these mice, as well as a small, but significant, reduction in the aggregation of mutant huntingtin in the striatal parenchyma in CBG-treated animals. In conclusion, our results open new research avenues for the use of CBG, alone or in combination with other phytocannabinoids or therapies, for the treatment of neurodegenerative diseases such as HD.

Key Words

Phytocannabinoids cannabigerol Huntington’s disease inflammation neuroprotection 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This work was supported by grants from CIBERNED (CB06/05/0089), MICINN (SAF2009/11847), and CAM (S2011/BMD-2308) to O.S. and S.V., and from MICINN (SAF2010/19292) and MINECO (IPT-2011-0861-900000) to E.M. These agencies had no further role in study design, the collection, analysis and interpretation of data, in the writing of the report, nor in the decision to submit the paper for publication. S.V. was supported by the Complutense University-Predoctoral Program. We are indebted to Yolanda García-Movellán for administrative assistance.

Conflict of interest

C.N. and M.L.B. are employees of VivaCell Biotechnology Spain and they were supported by MINECO IPT-2011-0861-900000 and FEDER-INTERCONNECTA ITC-20111029 grants to VivaCell Biotechnology.

Required Author Forms

Disclosure forms provided by the authors are available with the online version of this article.

Supplementary material

13311_2014_304_MOESM1_ESM.pdf (1.2 mb)
ESM1 (PDF 1224 kb)
13311_2014_304_MOESM2_ESM.pdf (1.2 mb)
ESM2 (PDF 1224 kb)
13311_2014_304_MOESM3_ESM.pdf (259 kb)
ESM3 (PDF 258 kb)

References

  1. 1.
    Roze E, Bonnet C, Betuing S, Caboche J. Huntington's disease. Adv Exp Med Biol 2010;685:45–63.CrossRefPubMedGoogle Scholar
  2. 2.
    Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010;90:905–981.CrossRefPubMedGoogle Scholar
  3. 3.
    Johnson CD, Davidson BL. Huntington's disease: progress toward effective disease-modifying treatments and a cure. Hum Mol Genet 2010;19:R98-R102.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Pazos MR, Sagredo O, Fernández-Ruiz J. The endocannabinoid system in Huntington's disease. Curr Pharm Des 2008;14:2317–2325.CrossRefPubMedGoogle Scholar
  5. 5.
    Fernández-Ruiz J, García C, Sagredo O, Gómez-Ruiz M, de Lago E. The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opin Ther Targets 2010;14:387–404.CrossRefPubMedGoogle Scholar
  6. 6.
    Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Fernández-Ruiz J, Brouillet E. Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. Neuroreport 2004;15:2375–2379.CrossRefPubMedGoogle Scholar
  7. 7.
    Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernández-Ruiz J. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci 2007;26:843–851.CrossRefPubMedGoogle Scholar
  8. 8.
    Blázquez C, Chiarlone A, Sagredo O, et al. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 2011;134:119–136.CrossRefPubMedGoogle Scholar
  9. 9.
    Palazuelos J, Aguado T, Pazos MR, et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 2009;132:3152–3164.CrossRefPubMedGoogle Scholar
  10. 10.
    Sagredo O, González S, Aroyo I, et al. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia 2009;57:1154–1167.CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Pintor A, Tebano MT, Martire A, et al. The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology 2006;51:1004–1012.CrossRefPubMedGoogle Scholar
  12. 12.
    Sastre-Garriga J, Vila C, Clissold S, Montalban X. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis. Expert Rev Neurother 2011;11:627–637.CrossRefPubMedGoogle Scholar
  13. 13.
    Zajicek JP, Apostu VI. Role of cannabinoids in multiple sclerosis. CNS Drugs 2011;25:187–201.CrossRefPubMedGoogle Scholar
  14. 14.
    Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. J Neurosci Res 2011;89:1509–1518.CrossRefPubMedGoogle Scholar
  15. 15.
    Fernández-Ruiz J, Sagredo O, Pazos MR, et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol 2013;75:323–333.CrossRefPubMedCentralPubMedGoogle Scholar
  16. 16.
    O'Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 2007;152:576–582.CrossRefPubMedCentralPubMedGoogle Scholar
  17. 17.
    Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009;30:515–527.CrossRefPubMedGoogle Scholar
  18. 18.
    Hill AJ, Williams CM, Whalley BJ, Stephens GJ. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther 2012;133:79–97.CrossRefPubMedGoogle Scholar
  19. 19.
    Granja AG, Carrillo-Salinas F, Pagani A, et al. A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis. J Neuroimmune Pharmacol 2012;7:1002–1016.CrossRefPubMedGoogle Scholar
  20. 20.
    Borrelli F, Fasolino I, Romano B, et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol 2013;85:1306–1316.CrossRefPubMedGoogle Scholar
  21. 21.
    Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG. Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br J Pharmacol 2010;159:129–141.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Brouillet E, Jacquard C, Bizat N, Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem 2005;95:1521–1540.CrossRefPubMedGoogle Scholar
  23. 23.
    Pouladi MA, Xie Y, Skotte NH, et al. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum Mol Genet 2010;19:1528–1538.CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    Fernagut PO, Diguet E, Stefanova N, et al. Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation. Neuroscience 2002;114:1005–1017.CrossRefPubMedGoogle Scholar
  25. 25.
    Luck H. Catalase. In: Bergmeyer HU (ed.) Methods of enzyme analysis. Academic Press, New York, 1971, p. 885.Google Scholar
  26. 26.
    Kono Y. Generation of superoxide radical during autoxidation of hydroxylamine and and assay for superoxide dismutase. Arch Biochem Biophys 1978;186:189–195.CrossRefPubMedGoogle Scholar
  27. 27.
    Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1978;82:70–77.CrossRefGoogle Scholar
  28. 28.
    Gray M, Shirasaki DI, Cepeda C, et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 2008;28:6182–6195.CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Alvarez FJ, Lafuente H, Rey-Santano MC, et al. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatr Res 2008;64:653–658.CrossRefPubMedGoogle Scholar
  30. 30.
    Trettel F, Rigamonti D, Hilditch-Maguire P, et al. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet 2000;9:2799–2809.CrossRefPubMedGoogle Scholar
  31. 31.
    Rangone H, Poizat G, Troncoso J, et al. The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur J Neurosci 2004;19:273–279.CrossRefPubMedGoogle Scholar
  32. 32.
    Tuohy TM, Wallingford N, Liu Y, et al. CD44 overexpression by oligodendrocytes: a novel mouse model of inflammation-independent demyelination and dysmyelination. Glia 2004;47:335–345.CrossRefPubMedGoogle Scholar
  33. 33.
    Glass M, Dragunow M, Faull RL. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000;97:505–519.CrossRefPubMedGoogle Scholar
  34. 34.
    Battista N, Bari M, Tarditi A, et al. Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes. Neurobiol Dis 2007;27:108–116.CrossRefPubMedGoogle Scholar
  35. 35.
    Apostol BL, Simmons DA, Zuccato C, et al. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol Cell Neurosci 2008;39:8–20.CrossRefPubMedGoogle Scholar
  36. 36.
    Estrada-Sánchez AM, Montiel T, Segovia J, Massieu L. Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters. Neurobiol Dis 2009;34:78–86.CrossRefPubMedGoogle Scholar
  37. 37.
    Luthi-Carter R, Strand A, Peters NL, et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 2000;9:1259–1271.CrossRefPubMedGoogle Scholar
  38. 38.
    Crocker SF, Costain WJ, Robertson HA. DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations. Brain Res 2006;1088:176–186.CrossRefPubMedGoogle Scholar
  39. 39.
    Deckel AW, Gordinier A, Nuttal D, et al. Reduced activity and protein expression of NOS in R6/2 HD transgenic mice: effects of L-NAME on symptom progression. Brain Res 2001;919:70–81.CrossRefPubMedGoogle Scholar
  40. 40.
    Yu ZX, Li SH, Evans J, Pillarisetti A, Li H, Li XJ. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J Neurosci 2003;23:2193–2202.PubMedGoogle Scholar
  41. 41.
    Zucker B, Luthi-Carter R, Kama JA, et al. Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1. Hum Mol Genet 2005;14:179–189.CrossRefPubMedGoogle Scholar
  42. 42.
    Jovicic A, Zaldivar Jolissaint JF, Moser R, Silva Santos Mde F, Luthi-Carter R. MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington's disease-related mechanisms. PLOS ONE 2013;8:e54222.CrossRefPubMedCentralPubMedGoogle Scholar
  43. 43.
    Mielcarek M, Benn CL, Franklin SA, et al. SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease. PLOS ONE 2011;6:e27746.CrossRefPubMedCentralPubMedGoogle Scholar
  44. 44.
    Rudinskiy N, Kaneko YA, Beesen AA, et al. Diminished hippocalcin expression in Huntington's disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons. J Neurochem 2009;111:460–472.CrossRefPubMedGoogle Scholar
  45. 45.
    Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 1991;40:701–708.CrossRefPubMedGoogle Scholar
  46. 46.
    Curtis A, Rickards H. Nabilone could treat chorea and irritability in Huntington's disease. J Neuropsychiatry Clin Neurosci 2006;18:553–554.PubMedGoogle Scholar
  47. 47.
    Curtis A, Mitchell I, Patel S, Ives N, Rickards H. A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov Disord 2009;24:2254–2259.CrossRefPubMedGoogle Scholar
  48. 48.
    Müller-Vahl KR, Schneider U, Emrich HM. Nabilone increases choreatic movements in Huntington's disease. Mov Disord 1999;14:1038–1040.CrossRefPubMedGoogle Scholar
  49. 49.
    Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors. ACS Chem Neurosci 2012;3:400–406.CrossRefPubMedCentralPubMedGoogle Scholar
  50. 50.
    Deiana S, Watanabe A, Yamasaki Y, et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl) 2012;219:859–873.CrossRefGoogle Scholar
  51. 51.
    Bode FJ, Stephan M, Wiehager S, et al. Increased numbers of motor activity peaks during light cycle are associated with reductions in adrenergic alpha(2)-receptor levels in a transgenic Huntington's disease rat model. Behav Brain Res 2009;205:175–182.CrossRefPubMedGoogle Scholar
  52. 52.
    Martel J, Chopin P, Colpaert F, Marien M. Neuroprotective effects of the alpha2-adrenoceptor antagonists, (+)-efaroxan and (+/−)-idazoxan, against quinolinic acid-induced lesions of the rat striatum. Exp Neurol 1998;154:595–601.CrossRefPubMedGoogle Scholar
  53. 53.
    Quintanilla RA, Jin YN, Fuenzalida K, Bronfman M, Johnson GV. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-γ (PPAR-γ) in the pathogenesis of Huntington disease. J Biol Chem 2008;283:25628–25637.CrossRefPubMedCentralPubMedGoogle Scholar
  54. 54.
    Johri A, Calingasan NY, Hennessey TM, et al. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Hum Mol Genet 2012;21:1124–1137.CrossRefPubMedCentralPubMedGoogle Scholar
  55. 55.
    Jin J, Albertz J, Guo Z, et al. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease. J Neurochem 2013;125:410–419.CrossRefPubMedCentralPubMedGoogle Scholar
  56. 56.
    Schütz B, Reimann J, Dumitrescu-Ozimek L, et al. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci 2005;25:7805–7812.CrossRefPubMedGoogle Scholar
  57. 57.
    Strum JC, Shehee R, Virley D, et al. Rosiglitazone induces mitochondrial biogenesis in mouse brain. J Alzheimers Dis 2007;11:45–51.PubMedGoogle Scholar
  58. 58.
    Strand AD, Baquet ZC, Aragaki AK, et al. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci 2007;27:11758–11768.CrossRefPubMedGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2014

Authors and Affiliations

  • Sara Valdeolivas
    • 1
    • 2
    • 3
  • Carmen Navarrete
    • 4
  • Irene Cantarero
    • 5
  • María L. Bellido
    • 4
  • Eduardo Muñoz
    • 5
  • Onintza Sagredo
    • 1
    • 2
    • 3
  1. 1.Departamento de Bioquímica y Biología MolecularInstituto Universitario de Investigación en Neuroquímica, Universidad ComplutenseMadridSpain
  2. 2.Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)Universidad ComplutenseMadridSpain
  3. 3.Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Facultad de MedicinaUniversidad ComplutenseMadridSpain
  4. 4.Vivacell Biotechnology SpainCórdobaSpain
  5. 5.Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBC)/Hospital Universitario Reina SofíaUniversidad de CórdobaCórdobaSpain

Personalised recommendations